COMMUNITY ONCOLOGY PRACTICE

MCED screening and broader genetic testing push community oncology toward prevention. Learn how practices adapt workflows, training, and follow-up for high-risk patients.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Why genetic tests aren’t enough: learn how counseling, risk models, and ongoing follow-up shape personalized screening and cancer prevention.

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured follow-up pathways for complex results and high-risk families.

Genetic testing reshapes community oncology, expanding hereditary screening to guide personalized surveillance, identify high-risk families, and shift care toward cancer prevention.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

Explore how allostatic load, using routine labs and vitals, may strengthen early-onset cancer risk prediction and guide earlier prevention in community oncology.

Community oncology moves beyond EMRs to intelligent records that embed AI, unify precision data, streamline trials, and cut clicks for better care.

Rising out-of-pocket costs push more adults to skip needed care, regardless of cancer history—highlighting financial toxicity and the need for smarter risk screening.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

Community oncology prepares for routine genetic testing, building workflows, training and follow-up to expand hereditary cancer risk care and reduce disparities.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

Timothy Hembree, DO, PhD, discusses how patients and physicians have benefited from an AI-supported virtual care system implemented at Moffitt Cancer Center.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely.

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

Early study data show community oncology matches or beats hospital cancer outcomes at lower cost, boosting local access, better experience, and payment reform calls.

Ohio State’s BRIDGE program coordinates age-tailored cancer care, tackling fertility, careers, and research gaps to transform outcomes for AYA patients.

A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, insights, and care.

Ohio State’s BRIDGE model unites research, wraparound care, digital tools and support services to improve outcomes in early-onset cancers.

Ohio State’s BRIDGE Program targets early-onset and AYA cancers, adding fertility, financial, and psychosocial support alongside specialists.

AACR data suggest 60% of early-onset cancers could be found with existing tests, prompting calls for earlier, risk-based screening.